# Opioid Use Disorder: Developing Depot Buprenorphine Products for Treatment - FDA Guidance Document

Source: https://www.globalkeysolutions.net/guidances/guidance-document/opioid-use-disorder-developing-depot-buprenorphine-products-for-treatment/f53ca142-5456-4eec-9cc0-358980e372cd

> FDA guidance document: Opioid Use Disorder: Developing Depot Buprenorphine Products for Treatment. Issue date: February 07, 2019. Get complete insights and analysis.

---

## Details

- Title: Opioid Use Disorder: Developing Depot Buprenorphine Products for Treatment
- Communication Type: Guidance Document
- Product Type: drugs
- Office Name: Center for Drug Evaluation and Research
- Office URL: /offices/center-for-drug-evaluation-and-research/cd980d74-1cbf-4226-ba9a-9045324c236c
- Issue Date: 2019-02-07
- Last Changed: 2020-01-17
- Docket Number: <a href="https://www.regulations.gov/docket/FDA-2018-D-1334">FDA-2018-D-1334</a>

## Related Documents

- [Allergic Rhinitis: Developing Drug Products for Treatment Guidance for Industry](https://www.globalkeysolutions.net/guidances/guidance-document/allergic-rhinitis-developing-drug-products-for-treatment-guidance-for-industry/dcca7128-d84a-436f-83a2-e705904c701f)
- [Nonallergic Rhinitis:  Developing Drug Products for Treatment](https://www.globalkeysolutions.net/guidances/guidance-document/nonallergic-rhinitis-developing-drug-products-for-treatment/5453a88f-6b6b-4771-8248-e324727993ad)
- [Migraine: Developing Drugs for Acute Treatment](https://www.globalkeysolutions.net/guidances/guidance-document/migraine-developing-drugs-for-acute-treatment/39ba4b4b-6c93-4849-a087-866c6bf4edff)